Core Scientific Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Core Scientific Inc trades at $15.62 (market cap $4.94B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.33 (market cap $2.27B). The key difference: Core Scientific Inc is far larger — about 2.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| CORZ | SLS | |
|---|---|---|
Market Cap | $4.94B | $2.27B |
Volume | 15,630,800 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $29.16 | $15.46 |
52-Week Low | $13.57 | $1.39 |
Typical Hold Time | 20 Days | — |
Enterprise Value | $7.46B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.94, down 4.44% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $288.62 million in 2025, with a negative net income margin of -324.9% in 2026. Recent news highlights its pivot to AI data center hosting and executive appointments, while analyst consensus remains strongly bullish with an 86.36% buy rating.
The outlook is mixed: strong analyst support and AI infrastructure growth offer upside potential, but persistent losses, high cash burn, and competitive pressures pose significant risks. Investors face volatility from execution challenges in the capital-intensive data center transition.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →